Search Results
112 Results Found for “stem cells”
Could NLRP3 be the missing link between amyloid pathology and tau-mediated neurodegeneration? Dr Gennaro Pagano explains how insights from the GRADUATE trial is informing the next generation of Alzheimer's disease therapies and advancing our understanding of neuroinflammation. https://touchmedicalmedia-1.wistia.
Meet the future leaders transforming neurology The touchNEUROLOGY Future Leaders 2026 programme recognizes outstanding early- and mid-career clinicians, researchers and scientists who are shaping the future of neurology. Nominated by peers across the global neurology community, these innovators are leading advances ...
We are delighted to announce Dr Björn Vahsen as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of research in amyotrophic lateral sclerosis and related neurodegenerative diseases Dr Björn Vahsen (Nuffield ...
New findings highlight the importance of functional antiviral immunity, beyond lymphocyte expansion alone, in progressive multifocal leukoencephalopathy. At American Academy of Neurology 2026, Dr Yair Mina (Staff Clinician, Experimental Immunotherapeutics Unit, National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, ...
Findings from the HOPE-3 phase 3 trial demonstrate positive effects on upper limb function and cardiac outcomes in Duchenne muscular dystrophy New phase 3 data presented at the American Academy of Neurology Annual Meeting 2026 highlight the potential of deramiocel as a novel ...
Between 60% and 80% of cases with dementia worldwide are caused by Alzheimer’s disease (AD), making it the most prevalent type of dementia.1 As of 2025, approximately 60 million people worldwide are affected by dementia, and by 2050, projections suggest a rise to nearly 210 ...
In this episode, Nicky speaks with Prof. Georgina Ellison-Hughes from King’s College London about the groundbreaking field of senolytics and their potential to advance the treatment of age-related diseases. From understanding the science behind cellular senescence to how senolytic drugs work and what early clinical trials reveal, this episode explores an exciting frontier in longevity medicine.
In general, headaches can be classified into primary headaches (where no underlying disease is found) and secondary headaches (where a predefined condition is the cause of the headache). According to the International Classification of Headache Disorders, third edition (ICHD-3), primary ...
At ECTRIMS 2025, leading experts in multiple sclerosis (MS) research and care reflected on the latest advances shaping the field. From novel immunotherapies and evolving B-cell treatment strategies to emerging insights into chronic inflammation, neuroprotection, and repair. Prof. Anders Svenningsson, Dr Marcello Moccia, and Dr Seema Kalra share their perspectives on some of the most promising developments and ongoing research challenges.
The RIDOSE-MS study investigated whether extending rituximab dosing intervals could maintain efficacy and reduce side effects in relapsing-remitting multiple sclerosis (RRMS). In this Q&A, we spoke with Prof. Anders Svenningsson, Professor of Neurology at Karolinska Institutet and consultant at Danderyd Hospital, Stockholm, about the background to the RIDOSE-MS trial, clinical insights on results, what the data reveal about long-term safety and efficacy, and how personalized dosing could shape future anti-CD20 treatment.
Prof. Joaquim Ferreira shares insights from EAN 2025 on the future of Parkinson’s disease care. He discusses realistic timelines for DMTs, the evolving role of gene therapy for genetic subgroups, and the potential of adaptive deep brain stimulation. Prof. Ferreira also highlights the growing importance of optimizing current treatments, interdisciplinary care, and addressing persistent challenges such as gait disturbance, dyskinesia, and cognitive decline.
Huntington’s disease (HD) is a neurodegenerative disease inherited in an autosomal dominant manner. It is caused by an expansion of cytosine, adenine, guanine (CAG) repeats within the huntingtin (HTT) gene, which is located on chromosome 4. This pathological expansion of ...
Neuromyelitis optica spectrum disorders (NMOSD) are a group of relapsing autoimmune diseases of the central nervous system. The clinical hallmarks of NMOSD are myelitis and optic neuritis; however, a wider clinical spectrum has been recognized.1Â The majority of patients with ...
Affecting over 70 million patients worldwide, epilepsy is a chronic neurological disorder characterized by intermittent bursts of hyper-synchronous neuronal discharges.1Â The manifestations are variable but reflective of the unique milieu and biology of epileptogenic foci.2Â Pharmacological treatment with antiepileptic drugs (AEDs) ...
Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory autoimmune disease of the central nervous system (CNS) with a worldwide distribution.1Â The first clinical description of NMOSD was made a century ago by Devic and Gault, who documented patients with ...
Introduction The term 'stroke' is used to describe an adverse clinical state involving interference of blood circulation to the brain due to obstruction or rupture of blood vessels.1Â Stroke was previously categorized into a cardiovascular disorder until the release of ...
Friedreich’s ataxia (FRDA), a neurodevelopmental and progressive neurodegenerative disease, is the most common inherited form of ataxia, with disease incidence as high as 1 in 29,000 in Caucasian populations.1 Patients typically present with ataxia from ages 7 to 15 years and lose the ...
Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system characterized by inflammation, demyelination and neurodegeneration. Natalizumab is a widely used anti-α4 integrin inhibitor for treating highly active MS. In the pivotal trials of natalizumab for MS, ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
